Here’s what you should know:
1. Takeda transferred a portion of its research business to the newly formed company.
2. Axcelead will combine Takeda’s drug discovery knowledge with its research facilities “to offer high-value drug discovery services.”
3. Axcelead will support Takeda’s group business efforts, but will also support other pharmaceutical companies, biotechnology ventures and research institutions.
More articles on improving performance:
2-level spinal fusions safe in outpatient settings, new study finds: 5 things to know
Xenco Medical launches spine system for ASCs nationally: 5 things to know
Influencing the bottom line — Dr. Allston Stubbs on diversified caseloads, growth and major specialties
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
